BioMed Research International / 2014 / Article / Tab 2 / Research Article
Synchronous and Metachronous Breast Malignancies: A Cross-Sectional Retrospective Study and Review of the Literature Table 2 Histology and TNM staging (AJCC/UICC) of the tumors at the time of diagnosis: in this table we present prevalences and
values referring to chi-square test.
UBC 1st MBC 2nd MBC 1st SBC 2nd SBC
Histology Ductal invasive carcinoma 65.91% (348/528) 69.23% (27/39) 65% (26/40) 43.75% (7/16) 68.75% (11/16) 0.447 Lobular invasive carcinoma 8.9% (47/528) 15.38% (6/39) 12.5% (5/40) 37.5% (6/16) 6.25% (1/16) <0.05 Ductal and lobular invasive carcinoma 13.45% (71/528) 7.69% (3/39) 5% (2/40) 12.5% (2/16) 6.25% (1/16) 0.418 Other invasive carcinomas 3.41% (18/528) 2.56% (1/39) 0% (0/40) 0% (0/16) 6.25% (1/16) 0.645 Ductal in situ carcinoma 7.39% (39/528) 5.13% (2/39) 17.5% (7/40) 6.25% (1/16) 6.25% (1/16) 0.212 Lobular in situ carcinoma 0.38% (2/528) 0% (0/39) 0% (0/40) 0% (0/16) 0% (0/16) 0.981 Unknown 0.57% (3/528) 0% (0/39) 0% (0/40) 0% (0/16) 6.25% (1/16) 0.067 Tumor (UICC) Tis-T1 67.94% (356/524) 68.42% (26/38) 70% (28/40) 62.5% (10/16) 75% (12/16) 0.957 T2 24.43% (128/524) 26.32% (10/38) 22.5% (9/40) 37.5% (6/16) 18.75% (3/16) 0.755 T3-T4 7.63% (40/524) 5.26% (2/38) 7.5% (3/40) 0% (0/16) 6.25% (1/16) 0.806 Lymph nodes (UICC) N0 66.86% (347/519) 75.68% (28/37) 70% (28/40) 56.25% (9/16) 93.75% (15/16) 0.122 N1 19.27% (100/519) 16.22% (6/37) 15% (6/40) 18.75% (3/16) 6.25% (1/16) 0.690 N2 7.51% (39/519) 2.7% (1/37) 10% (4/40) 12.5% (2/16) 0% (0/16) 0.476 N3 6.36% (33/519) 5.41% (2/37) 5% (2/40) 12.5% (2/16) 0% (0/16) 0.679